Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Autosomal Dominant Juvenile Parkinson Disease

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 2 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhao, Y1
Zhang, Q2
Xi, J1
Xiao, B1
Li, Y1
Ma, C1
He, Q1
Li, YH1
Guo, SS1
Wang, Y1
Lin, W1
Wang, J1
Ma, CG1
Xiao, BG1

Other Studies

2 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals

2015
Inhibition of Rho-kinase by Fasudil protects dopamine neurons and attenuates inflammatory response in an intranasal lipopolysaccharide-mediated Parkinson's model.
    The European journal of neuroscience, 2016, Volume: 43, Issue:1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intranasal; alpha-Synuclein; Animals;

2016